Literature DB >> 10555026

Significant loss of bone mass in patients with early, active ankylosing spondylitis: a followup study.

J Gratacós1, A Collado, F Pons, M Osaba, R Sanmartí, M Roqué, M Larrosa, J Múñoz-Gómez.   

Abstract

OBJECTIVE: To analyze whether inflammatory disease activity plays a substantial role in the loss of bone mass observed in ankylosing spondylitis (AS) patients who have not yet developed ankylosis.
METHODS: A longitudinal cohort study of 34 patients with early AS (duration <10 years) without ankylosis was conducted. The mean followup was 19 months. Loss of bone mass in defined regions of the lumbar spine and femoral neck was analyzed by dual x-ray absorptiometry. Patients were grouped according to biologic parameters of disease activity (erythrocyte sedimentation rate or C-reactive protein level). Group 1 consisted of 14 patients with active disease; group 2 comprised 20 patients with inactive disease. Serum levels of interleukin-6 (IL-6) and of hormones (sex, thyroid, and calciotropic), vertebral mobility (Schober test), daily physical activity, and treatment administered were recorded every 6 months for all patients.
RESULTS: At the end of the followup period, patients with active AS showed a significant reduction in bone mass in the lumbar spine (mean 1.01 gm/cm2 at study entry versus 0.961 gm/cm2 at followup [P = 0.005]) and femoral neck (0.849 gm/cm2 versus 0.821 gm/cm2 [P = 0.015]), which represented losses of 5% and 3%, respectively. In contrast, no significant reduction in bone mass was observed in patients with inactive AS. As expected, serum IL-6 levels were significantly higher in patients with active AS than in those with inactive disease (mean +/- SD 8.3 +/- 9 pg/ml versus 2.8 +/- 5 pg/ml [P = 0.008]). No significant differences were observed between the 2 groups in any of the other variables analyzed.
CONCLUSION: The observation that loss of bone mass in AS occurred only in patients with persistent active disease strongly suggests that inflammatory activity of the disease itself plays a major role in the pathophysiology of the early bone mineral disorders observed in these patients.

Entities:  

Mesh:

Year:  1999        PMID: 10555026     DOI: 10.1002/1529-0131(199911)42:11<2319::AID-ANR9>3.0.CO;2-G

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  47 in total

1.  Genetic determinants of IL-6 expression levels do not influence bone loss in inflammatory bowel disease.

Authors:  C Schulte; H Goebell; H D Röher; K M Schulte
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

2.  Osteoporosis in psoriatic arthritis: an assessment of densitometry and fragility fractures.

Authors:  Manuel Riesco; Francisco Manzano; Pilar Font; Alicia García; Joan M Nolla
Journal:  Clin Rheumatol       Date:  2013-07-12       Impact factor: 2.980

3.  The effect of IL-4 and MTHFR gene variants in ankylosing spondylitis.

Authors:  S Yigit; A Inanir; S Tural; B Filiz; A Tekcan
Journal:  Z Rheumatol       Date:  2015-02       Impact factor: 1.372

4.  Relative value of the lumbar spine and hip bone mineral density and bone turnover markers in men with ankylosing spondylitis.

Authors:  Laura Muntean; Marena Rojas-Vargas; Pilar Font; Siao-Pin Simon; Simona Rednic; Ruxandra Schiotis; Simona Stefan; Maria M Tamas; Horatiu D Bolosiu; Eduardo Collantes-Estévez
Journal:  Clin Rheumatol       Date:  2011-01-11       Impact factor: 2.980

5.  Bone turnover markers, anterior pituitary and gonadal hormones, and bone mass evaluation using quantitative computed tomography in ankylosing spondylitis.

Authors:  Abdellah El Maghraoui; Saida Tellal; Souad Chaouir; Khalil Lebbar; Ahmed Bezza; Abderrazak Nouijai; Lahsen Achemlal; Sanaa Bouhssain; El Mostapha Derouiche
Journal:  Clin Rheumatol       Date:  2004-12-08       Impact factor: 2.980

6.  [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 3 Clinical symptoms].

Authors:  U Kiltz; M Rudwaleit; J Sieper; D Krause; J-F Chenot; A Stallmach; S Jaresch; U Oberschelp; E Schneider; B Swoboda; H Böhm; A Heiligenhaus; U Pleyer; W-H Böhncke; M Stemmer; J Braun
Journal:  Z Rheumatol       Date:  2014-09       Impact factor: 1.372

7.  Risk factors for urolithiasis in patients with ankylosing spondylitis: a prospective case-control study.

Authors:  Emel Gönüllü; N Şule Yaşar Bilge; Döndü U Cansu; Müge Bekmez; Ahmet Musmul; Nevbahar Akçar; Timuçin Kaşifoğlu; Cengiz Korkmaz
Journal:  Urolithiasis       Date:  2016-08-19       Impact factor: 3.436

Review 8.  Inflammatory diseases and bone fragility.

Authors:  K Briot; P Geusens; I Em Bultink; W F Lems; C Roux
Journal:  Osteoporos Int       Date:  2017-09-15       Impact factor: 4.507

9.  Bone mineral density in patients with symptoms suggestive of spondyloarthritis.

Authors:  M Forien; A Moltó; A Etcheto; M Dougados; C Roux; K Briot
Journal:  Osteoporos Int       Date:  2015-01-28       Impact factor: 4.507

10.  Comorbidities in Argentine patients with axial spondyloarthritis: Is nephrolithiasis associated with this disease?

Authors:  Fernando Sommerfleck; Emilce Schneeberger; Gustavo Citera
Journal:  Eur J Rheumatol       Date:  2018-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.